A Single-Blind Dose-Ranging Pharmacodynamic Study of Auxora for the Treatment of Patients With Critical COVID-19 Pneumonia
Latest Information Update: 22 Aug 2022
At a glance
- Drugs Zegocractin (Primary)
- Indications COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
- Focus Pharmacodynamics
- Sponsors CalciMedica
- 17 Aug 2022 Status changed from active, no longer recruiting to completed.
- 10 May 2022 Status changed from recruiting to active, no longer recruiting.
- 08 Mar 2022 Planned End Date changed from 1 Oct 2021 to 1 Jun 2022.